
Arcturus Therapeutics has announced mid-year updates for ARCT-810, an investigational mRNA therapeutic to treat ornithine transcarbamylase (OTC) deficiency, and ARCT-032, …

Arcturus Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ARCT-032, …
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion

